20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-15 · Issuer identity, CIK and ticker cross-check.SEC APIAIDX SEC submissions APIRetrieved 2026-05-15 · Filing chronology and issuer metadata.SEC XBRL APIAIDX SEC companyfacts APIRetrieved 2026-05-15 · XBRL-derived financial cross-checks.Annual reportFY2025 Form 10-K2026-03-31 · Annual financials, revenue mix, business model, risks, liquidity, beneficial ownership and governance.ProspectusApril 2026 resale prospectus2026-04-13 · Public-company overview, selling-stockholder shares, risk factors and financing context.Form 8-KApril 28 Form 8-K2026-04-28 · Streeterville warrant repricing and financing amendment.Prospectus supplementApril 28 resale prospectus supplement2026-04-28 · Resale registration and warrant-amendment overhang.Exchange registrationForm 8-A2026-02-13 · Common stock registration on Nasdaq.Company releaseCompany direct-listing release2026-02-19 · Management's Nasdaq listing and growth narrative.Company releaseCompany FY2025 results release2026-04-15 · Latest earnings-style update and management commentary.Government sourceFDA Laboratory Developed Tests page2025-09-19 · Current LDT regulatory backdrop.Government sourceNCI Cancer Screening Research Network release2024-02-21 · Multi-cancer detection research context and evidence standard.